Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 2/2018

25.04.2018 | Mgmt. of Complex Cases in GI Oncology

Surgico-pathological Outcomes of 148 Radical Cholecystectomies Using Systematic Regional Lymphadenectomy Protocol: a Retrospective Study

verfasst von: Durgatosh Pandey, Pankaj Kumar Garg, Ashish Jakhetiya, Neelesh Jain, Shreyash Rai

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

Gallbladder cancer (GBC) is a potentially lethal malignancy among the biliary tract cancers with abysmal long-term survival. Surgery is the only curative treatment available for the management of GBC and, presently, provides the only ray of hope for long-term survival [1, 2]. Lymph node (LN) involvement is an important prognostic factor in GBC; lymphadenectomy is an indispensable part of radical resection [3]. American Joint Committee on Cancer 7th edition TNM staging for gallbladder cancer describes N1 nodes along the cystic duct, common bile duct, hepatic artery, and/or portal vein and N2 nodes as periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes [4]. AJCC staging manual further stages the presence of N2 nodes as stage IV disease; this nihilism has given rise to a marked controversy in the role and extent of lymphadenectomy. Though a number of studies have highlighted that the lymphadenectomy is associated with improved survival after surgery in GBC [57], literature is still not clear whether the total number of LNs retrieved, number of metastatic LNs, or their ratio or the location of LNs correlates with survival [8]. We believe that a systematic approach to regional lymphadenectomy is essential to maximize the lymph node yield based on the sound principles of surgical oncology. The present study shares our experience of radical cholecystectomies using a systematic regional lymphadenectomy protocol in a large cohort of patients with GBC. …
Literatur
1.
Zurück zum Zitat Pandey D, Garg PK, Manjunath NML, Sharma J. Extra-hepatic bile duct resection: an insight in the management of gallbladder cancer. J Gastrointest Cancer. 2015;46:291–6.CrossRefPubMed Pandey D, Garg PK, Manjunath NML, Sharma J. Extra-hepatic bile duct resection: an insight in the management of gallbladder cancer. J Gastrointest Cancer. 2015;46:291–6.CrossRefPubMed
2.
Zurück zum Zitat Garg PK, Pandey D. Gallbladder cancer: nihilism abates, optimism prevails. Eur J Surg Oncol. 2015;41:1443.CrossRefPubMed Garg PK, Pandey D. Gallbladder cancer: nihilism abates, optimism prevails. Eur J Surg Oncol. 2015;41:1443.CrossRefPubMed
3.
Zurück zum Zitat Garg PK, Pandey D, Sharma J. The surgical management of gallbladder cancer. Expert Rev Gastroenterol Hepatol. 2015;9:155–66.CrossRefPubMed Garg PK, Pandey D, Sharma J. The surgical management of gallbladder cancer. Expert Rev Gastroenterol Hepatol. 2015;9:155–66.CrossRefPubMed
4.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A editors. Gallbladder. In: AJCC cancer staging manual. Seventh edition. New York: Springer; p. 211–7. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A editors. Gallbladder. In: AJCC cancer staging manual. Seventh edition. New York: Springer; p. 211–7.
5.
Zurück zum Zitat Jensen EH, Abraham A, Jarosek S, Habermann EB, al-Refaie WB, Vickers SA, et al. Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery. 2009;146:706–11.CrossRefPubMed Jensen EH, Abraham A, Jarosek S, Habermann EB, al-Refaie WB, Vickers SA, et al. Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery. 2009;146:706–11.CrossRefPubMed
6.
Zurück zum Zitat Mayo SC, Shore AD, Nathan H, Edil B, Wolfgang CL, Hirose K, et al. National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg. 2010;14:1578–91.CrossRefPubMed Mayo SC, Shore AD, Nathan H, Edil B, Wolfgang CL, Hirose K, et al. National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg. 2010;14:1578–91.CrossRefPubMed
7.
Zurück zum Zitat Downing SR, Cadogan K-A, Ortega G, Oyetunji TA, Siram SM, Chang DC, et al. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: effect of extended surgical resection. Arch Surg. 2011;146:734–8.CrossRefPubMed Downing SR, Cadogan K-A, Ortega G, Oyetunji TA, Siram SM, Chang DC, et al. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: effect of extended surgical resection. Arch Surg. 2011;146:734–8.CrossRefPubMed
8.
Zurück zum Zitat Kim SH, Chong JU, Lim JH, Choi GH, Kang CM, Choi JS, et al. Optimal assessment of lymph node status in gallbladder cancer. Eur J Surg Oncol. 2016;42:205–10.CrossRefPubMed Kim SH, Chong JU, Lim JH, Choi GH, Kang CM, Choi JS, et al. Optimal assessment of lymph node status in gallbladder cancer. Eur J Surg Oncol. 2016;42:205–10.CrossRefPubMed
9.
Zurück zum Zitat Pandey D. Technical description of a regional lymphadenectomy in radical surgery for gallbladder cancer. HPB (Oxford). 2012;14:216–9.CrossRef Pandey D. Technical description of a regional lymphadenectomy in radical surgery for gallbladder cancer. HPB (Oxford). 2012;14:216–9.CrossRef
10.
11.
Zurück zum Zitat Sakata J, Shirai Y, Wakai T, Ajioka Y, Hatakeyama K. Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma. Ann Surg Oncol. 2010;17:1831–40.CrossRefPubMed Sakata J, Shirai Y, Wakai T, Ajioka Y, Hatakeyama K. Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma. Ann Surg Oncol. 2010;17:1831–40.CrossRefPubMed
12.
Zurück zum Zitat Shirai Y, Sakata J, Wakai T, Ohashi T, Ajioka Y, Hatakeyama K. Assessment of lymph node status in gallbladder cancer: location, number, or ratio of positive nodes. World J Surg Oncol. 2012;10:87.CrossRefPubMedPubMedCentral Shirai Y, Sakata J, Wakai T, Ohashi T, Ajioka Y, Hatakeyama K. Assessment of lymph node status in gallbladder cancer: location, number, or ratio of positive nodes. World J Surg Oncol. 2012;10:87.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Negi SS, Singh A, Chaudhary A. Lymph nodal involvement as prognostic factor in gallbladder cancer: location, count or ratio? J Gastrointest Surg. 2011;15:1017–25.CrossRefPubMed Negi SS, Singh A, Chaudhary A. Lymph nodal involvement as prognostic factor in gallbladder cancer: location, count or ratio? J Gastrointest Surg. 2011;15:1017–25.CrossRefPubMed
14.
Zurück zum Zitat Shirai Y, Yoshida K, Tsukada K, Ohtani T, Muto T. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg. 1992;79:659–62.CrossRefPubMed Shirai Y, Yoshida K, Tsukada K, Ohtani T, Muto T. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg. 1992;79:659–62.CrossRefPubMed
Metadaten
Titel
Surgico-pathological Outcomes of 148 Radical Cholecystectomies Using Systematic Regional Lymphadenectomy Protocol: a Retrospective Study
verfasst von
Durgatosh Pandey
Pankaj Kumar Garg
Ashish Jakhetiya
Neelesh Jain
Shreyash Rai
Publikationsdatum
25.04.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2018
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0106-3

Weitere Artikel der Ausgabe 2/2018

Journal of Gastrointestinal Cancer 2/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.